Anxiolytic effects of vestipitant in a sub-group of healthy volunteers known to be sensitive to CO2 challenge

Journal of Psychopharmacology

Volumn 28, Issue 5, 2014, Pages 491-497

  Poma, Stefano Zanone ^a,b   Merlo Pich, Emilio ^b   Bettica, Paolo ^b   Bani, Massimo ^b   Fina, Paolo ^c   Ziviani, Luigi ^b,d   Milleri, Stefano ^b,d  

^a UNIVERSITY OF PADOVA   (Italy)

^b GlaxoSmithKline Medicines Research Centre   (Italy)

^c GSK   (Italy)

^d Centro Ricerche Cliniche di Verona   (Italy)

Author keywords

alprazolam; carbon dioxide; Healthy volunteers; NK1 antagonists; vestipitant

Indexed keywords

ALPRAZOLAM; CARBON DIOXIDE; PLACEBO; VESTIPITANT; VOFOPITANT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; FLUOROBENZENE; PIPERIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ANXIETY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG SAFETY; FEMALE; HEADACHE; HEART RATE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PANIC SYMPTOM LIST; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SINGLE DRUG DOSE; SKIN CONDUCTANCE; TRANQUILIZING ACTIVITY; VISUAL ANALOG SCALE; ANXIETY DISORDERS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG THERAPY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; BENZODIAZEPINES; CARBON DIOXIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FLUOROBENZENES; HEART RATE; HUMANS; PIPERIDINES; TETRAZOLES; YOUNG ADULT;

EID: 84899866997     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113507641     Document Type: Article

References (33)

1. 2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology. 2002 ; 27: 715-729
2. 2 in human volunteers. Depress Anxiety. 2005 ; 21: 18-25
3. 2 model of GAD using paroxetine and lorazepam in healthy volunteers. J Psychopharmacol. 2007 ; 21: 42-49
4. 2 proof-of-concept experimental model of human anxiety. J Psychopharmacol. 2011a ; 25: 1199-1206
5. Bailey JE, Dawson GR, Dourish CT, et al. Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: A model of generalized anxiety disorder (GAD). J Psychopharmacol. 2011b ; 25: 1192-1198.
6. 2 challenge in panic disorder: Optimization by receiver operating characteristic (ROC) analysis. J Psychiat Res. 1995 ; 29: 111-119
7. 2-induced panic attacks in normal individuals. Psychoneuroendocrinology. 2013 ; 38: 2234-2242
8. Caldirola D, Bellodi L, Caumo A, et al. Approximate entropy of respiratory patterns in panic disorder. Am J Psychiatry. 2004a ; 161: 79-87
9. Caldirola D, Bellodi L, Cammino S, et al. Smoking and respiratory irregularity in panic disorder. Biol Psychiatry. 2004b ; 56: 393-398
10. Chambless DL, Caputo GC, Bright P, et al. Assessment of fear of fear in agoraphobics: The Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Cons Clin Psychol. 1984 ; 52: 1090
11. 2 inhalation in subjects at high-risk for panic disorder. J Affect Disord. 2006 ; 92: 63-70
12. Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des. 2009 ; 15: 1647-1674
13. Note for guidance on clinical investigations of medicinal products indicated for the treatment of Panic Disorders. London: CHMP-EMEA ; 2003 :
14. Forsyth JP, Eifert GH, Canna MA. Evoking analogue subtypes of panic attacks in a nonclinical population using carbon dioxide-enriched air. Behav Res Ther. 2000 ; 38: 559-572
15. Furmark T, Appel L, Michelgård A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry. 2005 ; 58: 132-142
16. Gorman JM, Browne ST, Papp LA, et al. Effect of antipanic treatment on response to carbon dioxide. Biol Psychiatry. 1997 ; 42: 982-991
17. Halasz J, Toth M, Mikics E, et al. The effect of eurokinin1 receptor blockade on territorial aggression and in a model of violent aggression. Biol Psychiatry. 2008 ; 63: 271-278
18. Heldt SA, Davis M, Ratti E, et al. Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils. J Behav Pharmacol. 2009 ; 20: 584-595
19. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance-P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006 ; 59: 216-223
20. Klein DF. False suffocation alarms, spontaneous panics and related conditions: An integrative hypothesis. Arch Gen Psychiatry. 1993 ; 50: 306-317
21. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockage of central Substance P receptors. Science. 1998 ; 281: 1640-1645
22. Malkesman O, Braw Y, Weller A. Assessment of antidepressant and anxiolytic properties of NK1 antagonists and substance P in Wistar Kyoto rats. Physiol Behav. 2007 ; 16: 619-625
23. Mathew SJ, Vythilingam M, Murrough JW, et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 ; 21: 221-229
24. McLean S. Do substance P and NK1 receptor have a role in depression and anxiety?. Curr Pharm Des. 2005 ; 11: 1529-1547
25. 2 models of anxiety: Differentiation of subjective and objective measures. J Psychopharmacol. 2010 ; 24: 649-656
26. 2 hyperreactivity and short-term treatment outcome. J Clin Psychopharmacol. 2002 ; 22: 300-308
27. Ratti E, Bellew K, Bettica P, et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol. 2011 ; 31: 727-733
28. 2-induced fear by 5-HTTLPR genotype. J Psychopharmacol. 2011 ; 25: 37-42
29. 2 challenge in generalized anxiety disorder. J Psychopharmacol. 2011 ; 25: 43-51
30. Sheehan DV, Lecrubier Y Mini International Neuropsychiatric Interview (M.I.N.I.). Tampa, FL: University of South Florida Institute for Research in Psychiatry ; 1994 :
31. Spielberger CD Manual for the State-Trait Anxiety Inventory, revised edition. Palo Alto, CA: Consulting Psychologists Press ; 1983 :
32. Woods SW, Krystal JH, Heninger GR, et al. Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects. Life Sci. 1989 ; 45: 233-242
33. 2) inhalation paradigm to evoke anxiety symptoms in healthy subjects. J Psychopharmachol. 2005 ; 19: 494-503